FAIR VALUE MEASUREMENTS (Tables)

3 Months Ended

Mar. 31, 2017

Summary of Estimated Fair Values of Financial Assets and Liabilities Measured on a Recurring Basis

The table which follows summarizes the estimated fair value of the Company’s financial assets and liabilities measured on a recurring basis as of March 31, 2017 and December 31, 2016:

Fair Value Measurements



	March 31, 2017		December 31, 2016
Financial Liabilities:	(amounts in thousands)
(Level 1)
Deferred compensation	$	1,213	$	1,472
(Level 3)
Convertible Notes derivative liability	$	—	$	27,532
Contingent consideration liabilities	$	5,773	$	5,603

Schedule of reconciliation of opening and closing balances for fair value measurements categorized within Level 3

The table which follows reconciles the opening balances to the closing balances for fair value measurements categorized within Level 3 of the fair value hierarchy:



	Contingent Consideration			Convertible Notes
	Liabilities (a)			Derivative Liability
	(amounts in thousands)
December 31, 2016	$	5,603		$	27,532
Settlements	(100		)	(25,951		)
Accretion expense	270			—
Valuation gain for the period	—			(1,581		)
March 31, 2017	$	5,773		$	—

_______________


(a)	Related to the Mediscan acquisition on October 30, 2015 and the USR acquisition on December 1, 2016. See Note 3 - Acquisitions. Valuation gain and accretion expense is included as acquisition-related contingent consideration on the condensed consolidated statements of operations.

Carrying Amounts and Estimated Fair Values of Significant Financial Instrument that were not Measured at Fair Value

The following table represents the carrying amounts and estimated fair value of the Company’s significant financial instruments that were not measured at fair value:



	March 31, 2017				December 31, 2016
	Carrying Amount		Fair Value		Carrying Amount		Fair Value
Financial Liabilities:			(amounts in thousands)
(Level 2)
Term Loan, net	$	38,161	$	39,300	$	39,137	$	41,500
Convertible Notes, net	$	—	$	—	$	20,331	$	27,250